Journal
CELL METABOLISM
Volume 34, Issue 7, Pages 969-+Publisher
CELL PRESS
DOI: 10.1016/j.cmet.2022.05.003
Keywords
-
Categories
Funding
- NIAAA [U01AA029019]
- NIEHS [5P42ES010337]
- NCATS [5UL1TR001442]
- NIDDK [U01DK130190, U01DK061734, R01DK106419, P30DK120515, R01DK121378, R01DK124318]
- NHLBI [P01HL147835]
- DOD PRCRP [W81XWH-18-2-0026]
- Arrowhead Pharmaceuticals
- AstraZeneca
- Boehringer-Ingelheim
- Bristol-Myers Squibb
- Eli Lilly
- Galectin Therapeutics
- Galmed Pharmaceuti-cals
- Gilead
- Intercept
- Hanmi
- Inventiva
- Ionis
- Janssen
- MadrigalPharmaceuticals
- Merck
- NGM Biopharmaceuticals
- Novo Nordisk
- Pfizer
- Sonic Incytes
- Terns Pharmaceuticals
- Singapore Ministry of Health's National Medical Research Council [MOH-000595-01]
- National Cancer Institute [R01 MD012565, U01 CA230694, R01 212008, R01 222900, R01 256977]
- NIH [1R01CA194307, 1R01CA215520-01, P30 DK 56338]
- GE Healthcare
- Canon Medical Systems Co.
- Lantheus Medical Imaging
- Bracco Diagnostics Inc.
- Cancer Prevention Research Institute of Texas [CAP-CAC RP190641]
- VA CSRD Merit Award [IIR 16I31.HB]
Ask authors/readers for more resources
Liver cancer epidemiology is changing due to factors such as increasing alcohol consumption, rising obesity rates, and advancements in hepatitis B and C treatment. The Global Burden of Disease study estimated global and regional trends in liver cancer burden, revealing a 25% increase in liver cancer deaths between 2010 and 2019. Non-alcoholic steatohepatitis (NASH) and alcohol were found to have the fastest growing death rates, while hepatitis B and C showed declines. Urgent measures are needed globally to address metabolic risk factors and slow the growing burden of NASH-associated liver cancer, particularly in the Americas.
Liver cancer epidemiology is changing due to increasing alcohol consumption, rising prevalence of obesity, and advances in hepatitis B virus (HBV) and hepatitis C virus (HCV) treatment. However, the impact of these changes on global liver cancer burden remains unclear. We estimated global and regional temporal trends in the burden of liver cancer and the contributions of various liver disease etiologies using the methodology framework of the Global Burden of Disease study. Between 2010 and 2019, there was a 25% increase in liver cancer deaths. Age -standardized death rates (ASDRs) increased only in the Americas and remained stable or fell in all other regions. Between 2010 and 2019, non-alcoholic steatohepatitis (NASH) and alcohol had the fastest growing ASDRs, while HCV and HBV declined. Urgent measures are required at a global level to tackle underlying metabolic risk factors and slow the growing burden of NASH-associated liver cancer, especially in the Americas.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available